Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.

Ohtuvayre (ensifentrine) is a first-in-class selective dual inhibitor of the enzymes phosphodiesterase three and phosphodiesterase 4 (“PDE3 and PDE4”) that combines bronchodilator and non-steroidal ...

Chronic obstructive lung disease, also known as chronic obstructive pulmonary disease (COPD), is a general term for a group ...

Changes in people’s voices recoded on a smartphone can signal a serious flare up in symptoms of chronic obstructive pulmonary ...

The National Medical Products Administration approved Dupixent as an add-on maintenance treatment for adults with ...

China NMPA approves Sanofi & Regeneron’s Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD: Paris Monday, September 30, 2024, 11:00 Hrs [IST] The Nat ...

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing ...

Dupixent is the first biologic medicine approved in the U.S. for the common lung condition, though competitors from GSK, AstraZeneca and Roche could follow.

The following is a summary of “Virtual reality for COPD exacerbation: A randomized controlled trial,” published in the August ...

With asthma and chronic obstructive pulmonary disease (COPD) on the rise, worsened by air pollution, tobacco use, and ...

N-acetylcysteine (NAC) nebulizer therapy is effective and safe as a short-term (12-week) treatment for reducing phlegm in chronic obstructive pulmonary disease (COPD), according to study findings ...